Why Are Biophytis Shares Skyrocketing Today?
Portfolio Pulse from Vandana Singh
Biophytis SA's shares are surging after the company concluded an agreement with SEQENS to produce the active compound in Sarconeos (BIO101), its main drug candidate. The drug is being developed for severe forms of Covid-19, sarcopenia, and Duchenne muscular dystrophy. Biophytis recently filed for FDA approval to launch its SARA-31 program in the U.S., the first-ever Phase 3 study in sarcopenia.
July 18, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biophytis' shares are surging after the company concluded a production agreement for its main drug candidate. The company also recently filed for FDA approval for its SARA-31 program.
The news of the production agreement for Sarconeos (BIO101) and the FDA filing for the SARA-31 program are both positive developments for Biophytis. These events are likely to increase investor confidence in the company, leading to a surge in its share price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100